Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex pays $60 million upfront to license two nucleotide polymerase inhibitors it will test in combination therapy with other HCV assets in its pipeline.